Soweto Clinical Trials Centre, Johannesburg, South Africa.
S Afr Med J. 2021 Feb 18;111(4):288-290. doi: 10.7196/SAMJ.2021.v111i4.15630.
Some South African (SA) healthcare practitioners are promoting the prescription and use of products claiming to contain ivermectin for the treatment and/or prevention of COVID-19 in SA. This study qualitatively analysed seven samples of ivermectin formulations (5 tablet and 2 capsule formulations) being sold in SA for human use. The samples were analysed using a high-performance liquid chromatography instrument connected to a Sciex X500R quadrupole time-of-flight high-resolution mass spectrometer. The study found that all the samples had both the major homologues of ivermectin (B1a and B1b) and also that 4 out of the 5 tablet formulations tested had at least one additional undeclared active pharmaceutical ingredient.
一些南非医疗从业者正在推荐开具和使用据称含有伊维菌素的产品，用于治疗和/或预防南非的 COVID-19。本研究对在南非销售的 7 种人用伊维菌素制剂（5 种片剂和 2 种胶囊制剂）进行了定性分析。使用连接到 Sciex X500R 四重极飞行时间高分辨率质谱仪的高效液相色谱仪对样品进行了分析。研究发现，所有样品均同时含有伊维菌素的主要同系物（B1a 和 B1b），而且在所测试的 5 种片剂制剂中有 4 种至少含有一种未申报的活性药物成分。
